An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, RFK Jr. advocated for easier access to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how regulators view compounded peptide therapies, which have drawn increasing interest from patients seeking alternatives to conventional drugs. Investigators say peptide treatments could reshape approaches to stubborn infections, though concerns about safety persist. The committee's endorsement of six peptides clears a path for more widespread prescribing, even as critics warn of long-term evidence. Market watchers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on certain peptide candidates.